Skyrizi and Humira are two AbbVie biologics for moderate-to-severe ulcerative colitis, but they work through very different mechanisms. Humira is the established anti-TNF standard with more than a decade of UC experience. Skyrizi is an IL-23 p19-selective biologic that gained UC approval in June 2024 based on the INSPIRE induction and COMMAND maintenance trials. For UC patients choosing between these drugs, the decision often comes down to mechanism, administration preferences, and expected long-term safety. This guide walks through the skyrizi vs humira ulcerative colitis decision.
Anti-TNF vs IL-23 p19 Mechanism
Humira (adalimumab) is a fully human monoclonal antibody that binds TNF-alpha and reduces inflammation systemically. Skyrizi (risankizumab) binds the p19 subunit of interleukin-23, selectively blocking IL-23 while leaving IL-12 intact. IL-23 drives the Th17 pathway that is central to UC inflammation. The risankizumab vs adalimumab UC distinction matters because mechanism shapes efficacy patterns and safety profiles. Humira's broader TNF blockade produces faster systemic anti-inflammatory effects and covers extraintestinal manifestations, but it comes with higher systemic infection risk. Skyrizi's narrower IL-23 targeting tends to produce cleaner long-term safety with strong endoscopic outcomes.
INSPIRE and COMMAND: Skyrizi's UC Evidence
INSPIRE was the pivotal phase 3 induction trial of risankizumab in UC. INSPIRE randomized biologic-naive and biologic-experienced UC patients to IV induction at weeks 0, 4, and 8 or placebo. At week 12, 20.3% of Skyrizi patients achieved clinical remission compared with 6.2% on placebo, with endoscopic improvement and symptomatic remission also significantly better. COMMAND was the maintenance trial that followed INSPIRE responders through 52 weeks. Patients randomized to continue Skyrizi SC maintenance at 180 mg or 360 mg every 8 weeks showed significantly higher rates of clinical remission, endoscopic improvement, and steroid-free remission than those switched to placebo. Humira's UC efficacy rests on the ULTRA-1 and ULTRA-2 trials, which established modest but meaningful benefit over placebo.
Efficacy Comparison
No head-to-head trial has compared Skyrizi with Humira in UC. Indirect comparisons from network meta-analyses suggest Skyrizi produces similar or slightly higher clinical remission rates than Humira in biologic-naive patients, with potentially better performance in anti-TNF experienced UC patients. For UC patients who have lost response to an anti-TNF, Skyrizi's INSPIRE subgroup analysis supports its use in this population. For biologic-naive patients, both drugs are reasonable first-line options with somewhat different safety and dosing trade-offs.
Onset of Action
Humira tends to produce early symptom improvement within the first few weeks of induction, consistent with the anti-TNF class. Skyrizi's UC onset is slightly slower, with meaningful response by week 4 to 8 and full response typically evident by week 12 based on INSPIRE. For UC patients with severe, active symptoms who need rapid control, Humira's fast onset sometimes matters clinically. For patients in less acute states or those prioritizing the IL-23 mechanism, Skyrizi's response trajectory is generally acceptable.
Safety Profiles
Humira carries anti-TNF class risks of serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Skyrizi's UC safety data from INSPIRE and COMMAND, combined with its extensive Crohn's and psoriasis experience, has been favorable with lower systemic infection rates than anti-TNFs. Injection-site and infusion-related reactions are mild with both drugs. For skyrizi vs humira UC side effects, UC patients with infection concerns, cancer history, or other risk factors often find Skyrizi's narrower immune footprint more reassuring. Both drugs require TB and hepatitis B screening before starting and both can be used as monotherapy.
Administration and Dosing
Humira is a subcutaneous injection throughout. UC induction is 160 mg on day 1 and 80 mg on day 15, followed by 40 mg every other week as maintenance, per AbbVie's prescribing information. Skyrizi for UC uses IV induction at weeks 0, 4, and 8 (1200 mg per infusion), followed by subcutaneous maintenance of 180 mg or 360 mg every 8 weeks depending on patient factors. For UC patients who want entirely home-based administration from the start, Humira is simpler. For patients willing to accept three IV induction doses in exchange for less frequent SC maintenance (every 8 weeks vs every other week), Skyrizi offers a more convenient long-term schedule.
Cost and Access
Humira faces extensive biosimilar competition. Multiple adalimumab biosimilars are designated interchangeable with Humira, including Amjevita, Cyltezo, Hyrimoz, Abrilada, Hulio, Simlandi, and Yuflyma. Many pharmacy benefit managers prefer biosimilar adalimumab. Skyrizi has no biosimilar and is priced as a branded biologic. For UC patients where insurance strongly favors a low-cost adalimumab biosimilar, Humira (or its biosimilar) may be the most accessible option. For patients whose plans cover Skyrizi and who prioritize the IL-23 mechanism, manufacturer copay assistance programs can help bridge the cost gap.
Choosing With Your GI
For a UC patient deciding between Skyrizi and Humira, both drugs offer meaningful response in biologic-naive patients. Humira tends to win on speed of onset, biosimilar cost savings, all-SC administration, and coverage of extraintestinal manifestations. Skyrizi tends to win on long-term safety, less frequent SC maintenance dosing, and performance in anti-TNF experienced patients per INSPIRE data. Ask your GI how response will be measured after induction, what to do if symptoms persist or return, and how your insurance handles adalimumab biosimilars versus branded IL-23 biologics. A log of stool frequency, urgency, blood, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.